Abbott Laboratories Announces REFLECT Real-World Studies Results That Shows Use Of FreeStyle Libre Continuous Glucose Monitoring Technology Associated With Significant Reduction In Risk Of Hospitalization For Heart Complications In People With Dia...

+1.77%

Abbott Laboratories

ABT

125.46

+1.77%

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1
This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1
Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.